U.S. prescription drug prices recorded their steepest year-over-year decline in more than six decades in the latest federal inflation data. The July Consumer Price Index, released August 12 by the Bureau of Labor Statistics, showed prescription drug prices down 0.8% from June and 3.1% from a year earlier, a shift the Trump White House quickly pointed to as evidence its affordability agenda is working. But researchers interviewed by national outlets said the data reflects a mix of forces, including a Medicare pricing framework created under President Joe Biden.
Federal data showed the largest annual prescription-drug price decline since 1963
The headline figure came from the July 2026 Consumer Price Index, which the Bureau of Labor Statistics released on August 12. According to reporting by the Associated Press and Axios, the prescription drug index fell 0.8% for the month and 3.1% from July 2025, marking the biggest year-over-year drop since 1963. That made prescription drugs one of the clearest areas of price relief in the latest inflation report.
President Donald Trump and his allies publicly took credit after the report was released. Administration messaging has also highlighted TrumpRx, a federal website launched earlier this year that directs consumers to discounted cash prices on some medications, according to Axios and earlier White House remarks archived by the American Presidency Project. Analysts cited by those outlets said the site may have helped some buyers, but they did not describe it as the sole driver of the national CPI change.
Health economists told the Associated Press that prescription drug pricing is unusually difficult to capture with one inflation measure because rebates, insurance design, and negotiated payments can all affect what consumers and payers actually spend. That means a CPI decline is meaningful, but it does not automatically show that every patient is paying less at the pharmacy counter.
For readers in any state, including local Medicare beneficiaries, the clearest confirmed takeaway is that the federal inflation gauge shows broad price declines in prescription drugs. What is not yet known from the CPI release is how evenly those savings are showing up across regions, pharmacy chains, employer plans, cash-pay purchases, and Medicare drug plans. Federal data in the inflation report is national, not state-by-state, and it does not provide a community-level breakdown of who benefited most.
That gap matters because people buy prescription drugs through different channels. Some patients pay cash, some rely on commercial insurance, and millions of older adults receive coverage through Medicare Part D plans with formularies and cost-sharing rules that can differ significantly. Experts cited by the Associated Press said consumers may not experience drug prices the same way they experience grocery or gasoline prices, where shelf prices are easier to compare.
There is also no comprehensive public list tying the July CPI decline to specific states or local pharmacies. The federal government has published negotiated Medicare prices for selected drugs, but it has not released a state-by-state accounting showing exactly how much of the July national decline came from each market.
The strongest documented explanation points back to the Inflation Reduction Act, signed by President Biden in August 2022. That law authorized Medicare, for the first time, to negotiate prices directly on certain high-spending drugs. The Centers for Medicare & Medicaid Services said the first set of negotiated maximum fair prices for 10 Medicare Part D drugs took effect on January 1, 2026, with some prices set well below prior list prices; CMS previously estimated Medicare would have saved about $6 billion across those drugs if the negotiated prices had been in place earlier.
Axios reported that the negotiated prices on the first 10 drugs were as much as 79% below list prices. Associated Press, citing drug-pricing specialists including the University of Southern California’s Erin Trish, reported that the Inflation Reduction Act’s policies are more likely to be directly related to the recent CPI change than current Trump administration initiatives alone. That does not rule out smaller contributions from Trump-era efforts, but it places the biggest structural explanation in a law enacted before he returned to office.
For consumers, the practical meaning is narrow but significant. The latest inflation data shows measurable national relief in prescription drug prices, while the largest verified policy change behind that trend remains Medicare negotiation under the 2022 law. CMS has said additional rounds of negotiated prices are scheduled in future years, extending the federal government’s role in shaping what some Americans pay for widely used medicines.